Solaris Endovascular announced that complete six-month results from its Phase II DEScover study of the investigational Solaris DE sirolimus-eluting covered stent will be presented at CIRSE 2026 in Copenhagen. The 120-patient study evaluates the device in patients with failing hemodialysis access circuits, including arteriovenous fistula and graft patients, with earlier interim results showing 95% target lesion primary patency and 82% access circuit primary patency at six months. Solaris DE combines a self-expanding nitinol scaffold, an electrospun-PTFE membrane, and controlled sirolimus delivery to address edge restenosis and received FDA Breakthrough Device Designation in 2026.
